Adequate sentinel node harvest is associated with low false negative rate in breast cancer managed with neoadjuvant chemotherapy and targeted axillary dissection
Autor: | Thomas L. Sutton, Nathalie Johnson, Jennifer R. Garreau |
---|---|
Rok vydání: | 2020 |
Předmět: |
medicine.medical_specialty
medicine.medical_treatment Sentinel lymph node Breast Neoplasms 03 medical and health sciences 0302 clinical medicine Breast cancer medicine Humans In patient Registries 030212 general & internal medicine False Negative Reactions Neoplasm Staging Retrospective Studies Chemotherapy Sentinel Lymph Node Biopsy business.industry Axillary Lymph Node Dissection General Medicine Middle Aged Sentinel node medicine.disease Neoadjuvant Therapy Axilla medicine.anatomical_structure Chemotherapy Adjuvant 030220 oncology & carcinogenesis Female Surgery Axillary Dissection Radiology Neoplasm Grading business |
Zdroj: | The American Journal of Surgery. 219:851-854 |
ISSN: | 0002-9610 |
Popis: | Introduction After neoadjuvant chemotherapy (NAC) for clinically node-positive breast cancer (NPBC), targeted axillary dissection (TAD) reduces the false negative rate (FNR) of axillary node sampling. Axillary lymph node dissection (ALND) is indicated if the clipped node cannot be identified. Prior studies have indicated that a sentinel lymph node harvest (SLNH) of ≥3 also leads to low FNR. We investigated the performance of SLNH thresholds at inferring the status of the axilla during TAD. Methods Retrospective review of the Legacy Health System Tumor Registry was performed. We identified NPBC patients between 2011 and 2016 managed with NAC and TAD. Results In 29 patients, the FNR of the SLNB component of TAD was 11% with SLNH of ≥3; with SLNH of ≤2 nodes the FNR was 20%. Conclusions In patients with NPBC receiving NAC, adequate SLNH is associated with acceptably low FNR. The decision to pursue ALND for clip identification should be made on a case-by-case basis. |
Databáze: | OpenAIRE |
Externí odkaz: |